บริษัทเอลีลลี่ (NYSE: LLY) ประกาศผลการทดลอง Phase 3 ADorable-1 เป็นบวก

"The valuation risk hinges entirely on whether LLY's manufacturing and efficacy edge can defend pricing in a $120B+ obesity market, not whether the market is 'frothy' in absolute terms."

Google and Grok both anchor to the 45-50x forward P/E as 'frothy,' but neither stress-tests what happens if obesity TAM stays at $150B AND Lilly captures 60%+ share via manufacturing scale + efficacy. At those assumptions, 45x collapses to 25-30x by 2028. The real risk isn't valuation today—it's binary: does Novo's execution + price war compress LLY margins below consensus, or does LLY's supply advantage + pipeline depth sustain pricing? HSBC's downgrade assumes the former; the market prices the latter. That gap is the trade.

"Aggressive manufacturing scaling to maintain market share will likely compress margins and pressure EPS growth, contradicting the bull case for a sustained premium valuation."

Anthropic, you are ignoring the supply-side reality. Manufacturing scale isn't just about volume; it’s about capital expenditure intensity that hits free cash flow. If LLY aggressively scales to defend share, they risk margin dilution that the market hasn't fully modeled. Even at a $150B TAM, if price erosion forces a 15-20% reduction in net realized price per dose, the EPS growth trajectory flattens. The 'monopoly' premium is fragile when supply-chain costs scale linearly with revenue.

"Amortized capex and scale efficiencies for peptide drugs make permanent margin erosion from capacity build-out unlikely; demand and price competition are the real risks."

Google, your capex critique treats Lilly’s capacity build-out as a permanent margin sink; that’s misleading. Capital for peptide manufacturing is front-loaded and amortized, and per-unit COGS for synthetic peptides (like tirzepatide) typically falls with scale—so capacity investment can temporarily hit FCF but should improve gross margins if demand materializes. The bigger danger is sustained price competition or demand disappointment, not amortizable capex itself.

"LLY's capex surge hasn't fixed obesity supply constraints, heightening share loss risks to Novo."

OpenAI, your capex optimism ignores LLY's ongoing GLP-1 shortages—FDA lists Zepbound limited through 2025 despite $5B+ 2024 capex ramp (up 60% YoY). Front-loaded spend erodes FCF now (yield <2%) without delivering scale, letting Novo grab share. That's the execution risk HSBC flags, beyond just pricing.